Yazar "Kanat M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The effect of feto-maternal blood type incompatibility on development of gestational diabetes mellitus
    (Societa Editrice Universo, 2014) Kanat M.; Goksugur S.B.; Ozlu T.; Tunckale A.; Ozturk B.; Ozturk F.Y.; Altuntas Y.; Suleymanoglu Y.; Atmaca H.; Yolcu N.; Gonenc I.; Delibasi T.; Zuhur S.; Dikbas O.; Aktas G.; Karagoz Y.; Abdul-Ghani M.A.
    Objective. To assess the relation between fetal and maternal blood type (ABO, Rh) incompatibility and development of gestational diabetes mellitus (GDM). Materials and Methods. A total of 500 pregnant women underwent diagnostic test for GDM by a 100-g oral glucose tolerance test (OGTT) after an 8 to 12-h overnight fast participated in this study. OGTT was performed between the 24-28 weeks of gestation, but participants who were at high risk for GDM were tested after the first prenatal visit. In the postpartum period, maternal and infant blood types were determined. Presence of GDM was evaluated in terms of matched and unmatched fetal and maternal ABO and Rh blood types separately. Results. GDM was detected in 235 participants. Unmatched ABO blood types between the mother-infant pairs were present in 44.7% (n=105) of GDM (+) and 35.8 % (n=95) of GDM (-) patients. Incompatible feto-maternal ABO blood type was positively correlated with development of GDM which was marginally significant. (p=0.045; R=1.2;95% CL; 1.004-1.48). However, Rh feto-maternal blood type incompatibility was not related with development of GDM. Conclusions. Feto-maternal ABO blood type incompatibility may be a weak risk factor for the development of GDM. © Società Editrice Universo (SEU).
  • Küçük Resim Yok
    Öğe
    Intensive Lipid Reduction and Proinflammatory Markers in the MODEST Study [Modest çaliflmas&203a;nda yog¨un lipid düflürücü tedavi ve proinflematuvar belirteçler]
    (Turkiye Klinikleri, 2010) Kanat M.; Yildiz O.; Tunçkale A.; Ceyhan B.O.; Karagöz Y.; Altuntafl Y.; Og¨uz A.
    Objective: Statin therapy is well known to reduce inflammatory markers such as tumor necrosis factor-?(TNF- ?), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP). However, whether this relationship is maintained in the setting of targeting very low levels of LDL (<70 mg dl) in patients with type 2 diabetes has not been clearly established. Materials and Methods: We measured hsCRP, IL-6, and TNF- ? in 43 subject enrolled into the multicenter, open-label, crossover prospective study evaluating the effects of lipid-lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST study). Subjects with diabetes and coronary artery disease were treated with 80 mg of atorvastatin for 12 weeks. The effect of treatment on pro-inflammatory markers was assessed after 12 weeks. Results: High-dose atorvastatin treatment significantly reduced the plasma levels of IL-6 and hsCRP (p<0.05, p<0.001, respectively), but not of TNF- ? (p=0.051). Conclusion: Atorvastatin treatment targeting very low LDL-cholesterol level reduced the levels of several important inflammatory markers in patients with type 2 diabetes and coronary heart disease.